🔎 Trials Near Me

Home › Neuroblastoma › NCT06831552

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

Recruiting

A Randomized Phase II Trial Evaluation of the Addition of the Resource Intervention to Support Equity (RISE) to Usual Supportive Care for Children With Newly Diagnosed High-Risk Neuroblastoma

Who can join

Up to age 17 · All sexes

Full eligibility criteria
Inclusion Criteria:

Patient cohort: The randomized Phase II multi-center RISE intervention will be conducted among a population of poverty-exposed children with high-risk neuroblastoma. Poverty will be a priori defined as parent-reported low-income (\<200% Federal Poverty Level). Children receiving treatment for cancer at study sites will serve as the study cohort, with parents/guardians as survey informants and intervention recipients on behalf of their minor children given that parents (not children) typically manage household finances.

* Patient newly diagnosed with high-risk neuroblastoma
* Patient has established care at study site and initiated cancer-directed therapy
* Patient has not yet initiated Induction Cycle 3
* Patient aged 0-17 years at the time of consent
* Parent/guardian screened positive for self-reported low-income (\<200% Federal Poverty) \*
* Family primary residence in MA, PA, IL, CA, WA, CT, GA, WI and OH
* Both patients co-enrolled on ANBL2131 or those receiving standard of care therapy at their center are eligible to participate
* Patients of all languages are eligible to participate

Exclusion Criteria:

* Foreign national family receiving care as an Embassy-pay patient.
* Child or household member receiving SSI

About the study

The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity \[Pediatric RISE\]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes.

Participants will be randomized to receive one of the following for 6-months:

* Usual supportive care alone or * Usual supportive care plus Pediatric RISE

What is being tested

Sponsor: Dana-Farber Cancer Institute · Participants: 84 · Started: Apr 30, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06831552

Locations in the U.S.

ConnecticutConnecticut Children's Medical Center, Hartford
GeorgiaChildren's Healthcare of Atlanta, Atlanta
MassachusettsDana-Farber Cancer Institute, Boston
PennsylvaniaChildren's Hospital of Philadelphia, Philadelphia
TexasUniversity of Texas Southwestern Medical Center, Dallas
WashingtonSeattle Children's Hospital, Seattle

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.